Developer docs
API playgroundTry for free, no card

Search company profiles

NX Development Corp.

Full company profile

uuid0004se5

Namestring
NX Development Corp.
Legal namestring
NX Development Corp.
Websiteurl
nxdevcorp.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

NX Development Corp. (NXDC) is a US-based life sciences company that commercializes Gleolan® (aminolevulinic acid hydrochloride / 5-ALA), an FDA-approved optical imaging agent indicated as an adjunct for visualization of malignant tissue during brain tumor resection in patients with glioma (suspected WHO Grades III or IV). Gleolan is administered orally at 20mg/kg 2-4 hours pre-surgery and acts as a prodrug metabolized intracellularly to Protoporphyrin IX, which accumulates selectively in tumor cells and emits red-violet fluorescence under blue light excitation (375-440nm), enabling real-time intraoperative visualization that complements conventional white-light microscopy. The company received original FDA approval in 2017 and is actively pursuing label expansion via the MEN-301 Phase 3 study for meningioma (supplemental NDA submitted April 2026) and the OVA-302 Phase 3 study for epithelial ovarian cancer (FDA Orphan Drug Designation granted March 2024).

The business is structured as a direct enterprise field sales operation targeting neurosurgery departments at US hospitals and surgical centers, with adoption across 400+ centers and 1,100+ surgeons in the United States and cumulative use in 120,000+ patients across 50+ countries. In April 2025, NXDC regained full US sales and marketing rights from Medexus Pharmaceuticals and relaunched Gleolan under the NXDC brand at the AANS conference in Boston; the company reported record-breaking unit sales in the one-year anniversary update through June 2026. Revenue derives from institutional, quote-based procurement of a single product with no publicly disclosed pricing. NXDC is a wholly-owned subsidiary of photonamic GmbH & Co. KG (Pinneberg, Germany), itself part of the SBI Holdings, Inc. (Tokyo) corporate group, providing integrated development and international commercialization infrastructure.

Short descriptiontext

NX Development Corp. is a US-based life sciences company that commercializes Gleolan®, an FDA-approved optical imaging agent enabling real-time fluorescence-guided brain tumor surgery, sold directly to neurosurgery departments across 400+ US hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fluorescence-guided surgery, intraoperative imaging agents, brain tumor visualization, optical imaging pharmaceuticals, neurosurgical oncology drugs
Industry2 codes
PRIMARYHLAKAIAL
Neuro-oncology
SECONDARYHLAKAFAH
Neuro-Oncology
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Intraoperative Optical Imaging Agents
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Gleolan Product Sales
TypeOne Time License
Description

NX Development Corp generates revenue through the sale of Gleolan (aminolevulinic acid HCl), an FDA-approved optical imaging agent used during brain tumor resection surgery. The company regained full commercial control of Gleolan in the US market in April 2025, reporting record-breaking unit sales in June 2026. Revenue is derived from direct sales to hospitals and surgical centers performing glioma and other cancer surgeries.

nxdevcorp.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NX Development Corp. develops and commercializes Gleolan® (aminolevulinic acid hydrochloride), an FDA-approved orally administered optical imaging agent used as an adjunct during brain tumor resection surgery. The prodrug is metabolized to Protoporphyrin IX, which selectively accumulates in malignant cells and fluoresces under blue light excitation, enabling neurosurgeons to visualize tumor tissue in real time during high-grade glioma surgery. The company also pursues expanded indications through Phase 3 clinical studies in meningioma and ovarian cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 120,000 patients have benefited from Gleolan use across over 50 countries
+2 more records
Product overview1 text field

NX Development Corp. offers a single flagship product—Gleolan®, an FDA-approved optical imaging agent used as an adjunct during brain cancer surgery. The drug is an orally-administered prodrug (aminolevulinic acid hydrochloride) that, when metabolized, causes tumor cells to fluoresce under blue light, enabling neurosurgeons to visualize and remove malignant tissue with precision in real-time. Originally approved in 2017 for high-grade glioma (WHO Grades III or IV), the company is actively pursuing expanded indications through clinical trials including meningioma (MEN-301 study) and ovarian cancer (OVA-302 study).

Product and service1 record
1Gleolan® (aminolevulinic acid hydrochloride)
CategoryFluorescence-Guided Surgery Imaging Agent
Description

FDA-approved oral optical imaging agent (ALA HCl / 5-ALA) administered at 20mg/kg body weight 2-4 hours prior to brain tumor resection. Metabolized to Protoporphyrin IX, which selectively accumulates in tumor cells and emits red-violet fluorescence under blue light (375-440nm), enabling real-time visualization of malignant tissue for neurosurgeons operating on high-grade glioma.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-23
Description

Medexus Pharmaceuticals previously held sales and marketing rights for Gleolan in the US market from 2022-2025. These rights returned to NXDC in April 2025. NXDC notes unresolved financial obligations remain due from Medexus that they are pursuing resolution for.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

In 2018, NX Development Corp became a subsidiary of Photonamic GmbH & Co. KG, a global leader in developing fluorescence-based diagnostic and therapeutic technologies. This partnership strengthened NXDC's market position and enabled expansion of Gleolan's reach. Photonamic is wholly owned by SBI ALApharma (Hong Kong), a subsidiary of SBI Holdings Inc. (Tokyo, Japan). Dr. Ulrich Kosciessa serves as both Chairman of NXDC's Board and CEO of Photonamic.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Parent company of NXDC and original developer of 5-ALA/ALA HCl technology. Operates the Gleolan franchise outside the US; directly comparable because it commercializes the same active ingredient in different geographies.

TypeEmerging player
Description

Clinical-stage developer of tumor-paint (fluorescent peptide) imaging agents for fluorescence-guided cancer surgery. Comparable as a focused fluorescence-guided surgery imaging company targeting the same surgical oncology end users.

TypeEmerging player
Description

Developer of an intraoperative fluorescence imaging system (LUM Imaging System) used to detect residual cancer during surgery. Comparable as a real-time intraoperative cancer visualization company with FDA pathway experience.

TypeOthers
Description

Former US commercial partner for Gleolan (2022–2025). Relevant because Medexus operated the same product in the same channel and serves as a directly comparable specialty pharma commercial model for NXDC's relaunch.

TypeBroad incumbent
Description

Public oncology specialty company commercializing Tumor Treating Fields (Optune) for glioblastoma and other solid tumors. Comparable as a focused brain-tumor oncology company selling a unique adjunct therapy into the same neurosurgery/neuro-oncology customer base.

TypeEmerging player
Description

Developer of an intraoperative/percutaneous hepatic delivery system with PHP for liver metastases. Comparable as a small specialty pharma/dev company commercializing an image-guided or procedure-adjacent oncology therapy through specialty centers.

TypeBroad incumbent
Description

Large medical device incumbent offering SPY fluorescence imaging platforms integrated into surgical suites. Comparable as a broader fluorescence-guided surgery imaging ecosystem player whose installed base and capital equipment shape Gleolan's addressable market.

TypeBroad incumbent
Description

Major manufacturer of surgical microscopes with blue-light fluorescence modules used in neurosurgery. Comparable as the dominant capital equipment provider whose microscope fleet enables Gleolan's blue-light workflow.

9Carl Zeiss Meditec
TypeBroad incumbent
Description

Manufacturer of surgical microscopes (e.g., OPMI Pentero) with integrated fluorescence modes used in glioma resection. Comparable as a key surgical microscope vendor that defines the technical environment for Gleolan's adoption.

10OnLume
TypeEmerging player
Description

Developer of fluorescence-guided surgery imaging hardware and software for veterinary and human surgical applications. Comparable as a smaller fluorescence-guided surgery imaging peer focused on intraoperative visualization.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NX Development Corp.

Intraoperative Optical Imaging Agentsnxdevcorp.com

NX Development Corp. is a US-based life sciences company that commercializes Gleolan®, an FDA-approved optical imaging agent enabling real-time fluorescence-guided brain tumor surgery, sold directly to neurosurgery departments across 400+ US hospitals.

What NX Development Corp. does

NX Development Corp. (NXDC) is a US-based life sciences company that commercializes Gleolan® (aminolevulinic acid hydrochloride / 5-ALA), an FDA-approved optical imaging agent indicated as an adjunct for visualization of malignant tissue during brain tumor resection in patients with glioma (suspected WHO Grades III or IV). Gleolan is administered orally at 20mg/kg 2-4 hours pre-surgery and acts as a prodrug metabolized intracellularly to Protoporphyrin IX, which accumulates selectively in tumor cells and emits red-violet fluorescence under blue light excitation (375-440nm), enabling real-time intraoperative visualization that complements conventional white-light microscopy. The company received original FDA approval in 2017 and is actively pursuing label expansion via the MEN-301 Phase 3 study for meningioma (supplemental NDA submitted April 2026) and the OVA-302 Phase 3 study for epithelial ovarian cancer (FDA Orphan Drug Designation granted March 2024).

The business is structured as a direct enterprise field sales operation targeting neurosurgery departments at US hospitals and surgical centers, with adoption across 400+ centers and 1,100+ surgeons in the United States and cumulative use in 120,000+ patients across 50+ countries. In April 2025, NXDC regained full US sales and marketing rights from Medexus Pharmaceuticals and relaunched Gleolan under the NXDC brand at the AANS conference in Boston; the company reported record-breaking unit sales in the one-year anniversary update through June 2026. Revenue derives from institutional, quote-based procurement of a single product with no publicly disclosed pricing. NXDC is a wholly-owned subsidiary of photonamic GmbH & Co. KG (Pinneberg, Germany), itself part of the SBI Holdings, Inc. (Tokyo) corporate group, providing integrated development and international commercialization infrastructure.

NX Development Corp. firmographics

Firmographics
Name
NX Development Corp.
Legal name
NX Development Corp.
Website
https://nxdevcorp.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
NX Development Corp. is a US-based life sciences company that commercializes Gleolan®, an FDA-approved optical imaging agent enabling real-time fluorescence-guided brain tumor surgery, sold directly to neurosurgery departments across 400+ US hospitals.
Ownership category
akta.pro rank

NX Development Corp. industry classification

Industry
Product category
Intraoperative Optical Imaging Agents
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAKAIAL
Neuro-oncology
SECONDARYHLAKAFAH
Neuro-Oncology

Keywords

  • Fluorescence-guided surgery
  • Intraoperative imaging agents
  • Brain tumor visualization
  • Optical imaging pharmaceuticals
  • Neurosurgical oncology drugs

Where NX Development Corp. is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NX Development Corp. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Gleolan Product Sales: NX Development Corp generates revenue through the sale of Gleolan (aminolevulinic acid HCl), an FDA-approved optical imaging agent used during brain tumor resection surgery. The company regained full commercial control of Gleolan in the US market in April 2025, reporting record-breaking unit sales in June 2026. Revenue is derived from direct sales to hospitals and surgical centers performing glioma and other cancer surgeries.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

NX Development Corp. product offering

Product offering

Core offering

NX Development Corp. develops and commercializes Gleolan® (aminolevulinic acid hydrochloride), an FDA-approved orally administered optical imaging agent used as an adjunct during brain tumor resection surgery. The prodrug is metabolized to Protoporphyrin IX, which selectively accumulates in malignant cells and fluoresces under blue light excitation, enabling neurosurgeons to visualize tumor tissue in real time during high-grade glioma surgery. The company also pursues expanded indications through Phase 3 clinical studies in meningioma and ovarian cancer.

Product overview

NX Development Corp. offers a single flagship product—Gleolan®, an FDA-approved optical imaging agent used as an adjunct during brain cancer surgery. The drug is an orally-administered prodrug (aminolevulinic acid hydrochloride) that, when metabolized, causes tumor cells to fluoresce under blue light, enabling neurosurgeons to visualize and remove malignant tissue with precision in real-time. Originally approved in 2017 for high-grade glioma (WHO Grades III or IV), the company is actively pursuing expanded indications through clinical trials including meningioma (MEN-301 study) and ovarian cancer (OVA-302 study).

Differentiator

Problem solved

Functional benefit

Products and services

  • Gleolan® (aminolevulinic acid hydrochloride) FDA-approved oral optical imaging agent (ALA HCl / 5-ALA) administered at 20mg/kg body weight 2-4 hours prior to brain tumor resection. Metabolized to Protoporphyrin IX, which selectively accumulates in tumor cells and emits red-violet fluorescence under blue light (375-440nm), enabling real-time visualization of malignant tissue for neurosurgeons operating on high-grade glioma.

Quantifiable outcome

  • Over 120,000 patients have benefited from Gleolan use across over 50 countries
  • +2 more outcomes

Companies that use NX Development Corp.

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

NX Development Corp. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NX Development Corp. partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Medexus Pharmaceuticals (Former)minorChannel Partner/ Reseller/ Distributor · 23 April 2025Medexus Pharmaceuticals previously held sales and marketing rights for Gleolan in the US market from 2022-2025. These rights returned to NXDC in April 2025. NXDC notes unresolved financial obligations remain due from Medexus that they are pursuing resolution for.
  • Photonamic GmbH & Co. KGcoreStrategic or Co-development Partner · 1 January 2018In 2018, NX Development Corp became a subsidiary of Photonamic GmbH & Co. KG, a global leader in developing fluorescence-based diagnostic and therapeutic technologies. This partnership strengthened NXDC's market position and enabled expansion of Gleolan's reach. Photonamic is wholly owned by SBI ALApharma (Hong Kong), a subsidiary of SBI Holdings Inc. (Tokyo, Japan). Dr. Ulrich Kosciessa serves as both Chairman of NXDC's Board and CEO of Photonamic.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

NX Development Corp. competitors and assessment

Company assessment

Direct peers

  • Photonamic GmbH & Co. KG: Parent company of NXDC and original developer of 5-ALA/ALA HCl technology. Operates the Gleolan franchise outside the US; directly comparable because it commercializes the same active ingredient in different geographies.

Emerging players

  • Blaze Bioscience: Clinical-stage developer of tumor-paint (fluorescent peptide) imaging agents for fluorescence-guided cancer surgery. Comparable as a focused fluorescence-guided surgery imaging company targeting the same surgical oncology end users.
  • Lumicell: Developer of an intraoperative fluorescence imaging system (LUM Imaging System) used to detect residual cancer during surgery. Comparable as a real-time intraoperative cancer visualization company with FDA pathway experience.
  • Delcath Systems: Developer of an intraoperative/percutaneous hepatic delivery system with PHP for liver metastases. Comparable as a small specialty pharma/dev company commercializing an image-guided or procedure-adjacent oncology therapy through specialty centers.
  • OnLume: Developer of fluorescence-guided surgery imaging hardware and software for veterinary and human surgical applications. Comparable as a smaller fluorescence-guided surgery imaging peer focused on intraoperative visualization.

Others

  • Medexus Pharmaceuticals: Former US commercial partner for Gleolan (2022–2025). Relevant because Medexus operated the same product in the same channel and serves as a directly comparable specialty pharma commercial model for NXDC's relaunch.

Broad incumbents

  • Novocure: Public oncology specialty company commercializing Tumor Treating Fields (Optune) for glioblastoma and other solid tumors. Comparable as a focused brain-tumor oncology company selling a unique adjunct therapy into the same neurosurgery/neuro-oncology customer base.
  • Stryker (Surgical Imaging): Large medical device incumbent offering SPY fluorescence imaging platforms integrated into surgical suites. Comparable as a broader fluorescence-guided surgery imaging ecosystem player whose installed base and capital equipment shape Gleolan's addressable market.
  • Leica Microsystems (Danaher): Major manufacturer of surgical microscopes with blue-light fluorescence modules used in neurosurgery. Comparable as the dominant capital equipment provider whose microscope fleet enables Gleolan's blue-light workflow.
  • Carl Zeiss Meditec: Manufacturer of surgical microscopes (e.g., OPMI Pentero) with integrated fluorescence modes used in glioma resection. Comparable as a key surgical microscope vendor that defines the technical environment for Gleolan's adoption.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

NX Development Corp. social profiles

Digital presence

NX Development Corp. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NX Development Corp. leadership team

Management profile

Number of profiles

Profiles2 records

NX Development Corp. funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NX Development Corp. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NX Development Corp.

What does NX Development Corp. do?

NX Development Corp. develops and commercializes Gleolan® (aminolevulinic acid hydrochloride), an FDA-approved orally administered optical imaging agent used as an adjunct during brain tumor resection surgery. The prodrug is metabolized to Protoporphyrin IX, which selectively accumulates in malignant cells and fluoresces under blue light excitation, enabling neurosurgeons to visualize tumor tissue in real time during high-grade glioma surgery. The company also pursues expanded indications through Phase 3 clinical studies in meningioma and ovarian cancer.

Is NX Development Corp. a public or private company?

NX Development Corp. is a private company. It is classified as corporate owned and is currently operating.

When was NX Development Corp. founded?

NX Development Corp. was founded in 2010. It employs 11 to 50 people.

Where is NX Development Corp. based?

NX Development Corp. is headquartered in Lexington, United States, in the North America region.

How does NX Development Corp. make money?

One revenue line is on record: gleolan Product Sales.

Who are NX Development Corp.'s main competitors?

Photonamic GmbH & Co. KG is listed as a direct peer. Emerging players are Blaze Bioscience, Lumicell, Delcath Systems and OnLume. Medexus Pharmaceuticals is listed as an others. Broad incumbents are Novocure, Stryker (Surgical Imaging), Leica Microsystems (Danaher) and Carl Zeiss Meditec.

Does NX Development Corp. have an API?

No public API is recorded for NX Development Corp..

What industry is NX Development Corp. in?

NX Development Corp.'s product category is Intraoperative Optical Imaging Agents. Its primary akta.pro industry code is HLAKAIAL, Neuro-oncology, with a secondary code of HLAKAFAH, Neuro-Oncology. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageNX Development Corp. Celebrates One-Year Anniversary of Gleolan(R) Commercial Control With Record-Breaking SalesNX Development Corp. celebrated the one-year anniversary of its commercial control over Gleolan, an optical imaging agent used as an adjunct for visualizing malignant tissue during glioma surgery, reporting record-breaking unit sales and significant customer base growth over the period. The company noted that unresolved financial obligations remain due from its former Gleolan commercialization partner in the US, which it is pursuing resolution for. NX Development Corp. is a wholly owned subsidiary of photonamic GmbH & Co. KG, which belongs to the SBI Holdings Inc. Group.BioSpaceNX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 StudyNX Development Corp announced the submission of supplemental data from its MEN-301 Study to the FDA as an efficacy supplement to the Gleolan New Drug Application, covering the use of aminolevulinic acid HCl for enhanced visualization during meningioma surgery. This marks the first supplemental NDA submission since Gleolan's original 2017 FDA approval for high-grade glioma. The company, acquired by photonamic GmbH & Co. KG in 2018, described the submission as a milestone in advancing fluorescence-guided surgery for patients and healthcare professionals.PharmiWeb.comNX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 StudyNX Development Corp announced on April 6, 2026, the submission of supplemental data from its MEN-301 Study to the FDA as an efficacy supplement to its existing Gleolan New Drug Application, marking the first supplemental submission since the original 2017 approval for high-grade glioma. The study examined the use of Gleolan (aminolevulinic acid HCl) to enhance visualization of newly diagnosed or recurrent meningioma during fluorescence-guided surgery. The company's CEO and Board Chairman characterized the submission as a significant milestone for the company and for advancing the science of fluorescence-guided surgery globally.GlobeNewswireNX Development Corp. (NXDC) Names Salvatore DeSena, M.D., as Chief Executive OfficerNX Development Corp. named Salvatore DeSena, M.D., as CEO on March 2, 2022. He brings medical affairs and imaging experience, including founding a teleradiology service. The company will focus on new 5-ALA indications via clinical trials, with Medexus Pharma handling U.S. sales of Gleolan.GlobeNewswireNX Development Corp. (NXDC) Names Salvatore DeSena, M.D., as Chief Executive OfficerNX Development Corp. named Salvatore DeSena, M.D., as CEO on March 2, 2022. The hire follows a commercial partnership with Medexus Pharma, which assumed sales of Gleolan in the U.S. as of March 1, 2022. NX Development will focus on new 5-ALA indications via clinical trials.GlobeNewswireT.J. Stalvey Joins NX Development Corp. (NXDC) as Vice President of Clinical Development and Medical AffairsNX Development Corp. named T.J. Stalvey as Vice President of Clinical Operations, bringing over 20 years of clinical operations and medical affairs experience. He will oversee Phase I-III trial planning and medical affairs for Gleolan, including field education and medical information. The company plans to build supplemental indications for Gleolan.GlobeNewswireT.J. Stalvey Joins NX Development Corp. (NXDC) as Vice President of Clinical Development and Medical AffairsNX Development Corp. named T.J. Stalvey as Vice President of Clinical Operations, bringing over 20 years of clinical operations and medical affairs experience. He will oversee Phase I-III trial planning and new development programs, including medical affairs for Gleolan, an FDA-approved optical imaging agent for glioma surgery.GlobeNewswireNX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in MeningiomaNX Development Corp. received FDA orphan-drug designation for Gleolan for meningioma visualization. The Phase III study (NXDC-MEN-301) enrolls 100 patients and is expected to complete in about 15 months. The company plans to expand Gleolan's surgical use across tumor types.GlobeNewswireNX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)NX Development Corp. announced the first patient enrollment in a Phase III study of Gleolan for meningioma visualization. The international trial will enroll 100 patients and is expected to complete in about 15 months. The study aims to show benefits of fluorescence-guided surgery for distinguishing tumor from non-tumor tissue.YahooNX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)NX Development Corp. announced the first patient enrollment in a Phase III trial of Gleolan for meningioma visualization. The international study will enroll 100 patients and is expected to complete in about 15 months. The trial aims to show benefits of fluorescence-guided surgery for distinguishing tumor from non-tumor tissue.